Wilson Sonsini is a proud supporter of the 2nd Annual Virtual Due Diligence Master Class, June 21, 22 and 23, presented by The Entrepreneurship Lab NYC (ELabNYC), an initiative of the New York City Economic Development Corporation (NYCEDC) and led by FirstXFounder. Ventures will choose from two tracks covering Pre-Seed and Seed/Series A funding. In addition, attendees will have the opportunity to network with speakers and other attendees at an in-person reception on June 21st from 5:30 PM-7:30 PM in Mid-Town Manhattan.
Investors and Life Science Founders will share their due diligence expectations and strategies to help ventures level up their due diligence skills. The topics discussed include Funding Trends, Investors First Meeting Expectations, Due Diligence Checklists, Financial Model Expectations, IP Due Diligence check lists, Global Trends, Series B and Exit Strategies, and more.
The Master Class will feature Wilson Sonsini attorney, Craig Kenesky as a speaker on IP Due Diligence and additional panelists and session leaders from 2048 Ventures, Angel Investor Forum, Canaan, CT Innovations, Cytodyn, DHNY, Future Fund, Golden Seeds, JelikaLite, JP Morgan, Moses Singer, NY Ventures, Orange Grove Bio, Osage University Partners, RA Ventures, VC23 Investors, VitaDAO, Westchester Angels, Wiggin, and Xontogeny.
Sonia El-Feki
selfeki@wsgr.comDr. Craig Kenesky is an associate in the New York office of Wilson Sonsini Goodrich & Rosati. Craig applies his background in synthetic organic, medicinal, peptide, bioorganic, and computational chemistry to the prosecution of domestic and foreign patent applications, as well as due diligence, freedom to operate, portfolio development strategy, opinions, and IP counseling. Craig represents clients in numerous technology-focused industries, including the chemical, pharmaceutical, biotechnology, nanotechnology, diagnostic, neutriceutical, healthcare, process and manufacturing, energy, clean technology, biofuel, genomics, software, information technology, bioinformatics, scientific instrument, personalized medicine, and medical device sectors. He performs pre-transaction due diligence on behalf of both technology companies and venture capital groups, and he develops non-infringement and invalidity strategies for generic pharmaceutical companies.